ML
Marc Larkins Portfolio
Invests via Johnson & Johnson | Managed by Marc Larkins
Invests via Johnson & Johnson
Managed by Marc Larkins
Automatically Tracked
Marc Larkins Profile
Marc Larkins is a seasoned entrepreneur known for his innovative approach in the tech sector. With an impressive track record of launching successful startups, he has consistently driven growth through strategic vision and execution. His background spans engineering and business management, allowing him to blend technical expertise with market insights effectively. Larkins has cultivated a reputation as a thought leader within the entrepreneurial community, fostering collaboration among emerging companies and established industry players alike. His ability to identify unique market opportunities positions him as a significant influencer in technology commercialization.
Marc Larkins is a seasoned entrepreneur known for his innovative approach in the tech sector. With an impressive track record of launching successful startups, he has consistently driven growth through strategic vision and execution. His background spans engineering and business management, allowing him to blend technical expertise with market insights effectively. Larkins has cultivated a reputation as a thought leader within the entrepreneurial community, fostering collaboration among emerging companies and established industry players alike. His ability to identify unique market opportunities positions him as a significant influencer in technology commercialization.
Investment Philosophy & Strategy
Opportunity identification is at the core of Marc Larkins' investment philosophy, driven by a deep understanding of technology and market dynamics. His entrepreneurial journey informs a proactive strategy focused on scalable ventures that challenge conventional industry paradigms. With expertise in both engineering and business, he gravitates towards startups poised for disruption, prioritizing innovation as the key to sustained growth. Larkins' unique ability to harness technical knowledge enables him to navigate complex landscapes, forming strategic alliances that amplify value creation across sectors. By fostering collaboration among diverse stakeholders, he enhances his portfolio’s adaptability while aiming for transformative outcomes.
Opportunity identification is at the core of Marc Larkins' investment philosophy, driven by a deep understanding of technology and market dynamics. His entrepreneurial journey informs a proactive strategy focused on scalable ventures that challenge conventional industry paradigms. With expertise in both engineering and business, he gravitates towards startups poised for disruption, prioritizing innovation as the key to sustained growth. Larkins' unique ability to harness technical knowledge enables him to navigate complex landscapes, forming strategic alliances that amplify value creation across sectors. By fostering collaboration among diverse stakeholders, he enhances his portfolio’s adaptability while aiming for transformative outcomes.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
23.54%
Gain
Monthly
-0.24%
Yearly
-2.85%
Drawdown
56.44%
$814.17M
Equity
Holdings
$814.17M
Investment
$611.79M
$48.16M
Profit -$3.74M
Realized
-$154.22M
Unrealized
$202.38M
Dividends
$72.93M
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
0%
Profit
-$3.74M
Win %
35%
This Week
Compared To Last Week
Gain
5.25%
Profit
$40.6M
Win %
35%
This Month
Compared to last month
Gain
4.57%
Profit
$35.61M
Win %
35%
This Year
Compared to last year
Gain
24.81%
Profit
$161.82M
Win %
32%
PTGX Protagonist Therapeutics Inc.
+3.46%
+$11.12M 
LAB Standard Biotools Inc.
+3.27%
+$8,547.9 
NMRA Neumora Therapeutics, Inc.
+2.85%
+$83,225.02 
MGTX MeiraGTx Holdings plc
+2.01%
+$1.66M 
RLYB Rallybio Corporation
+1.69%
+$41,283.27 
CVRX CVRx, Inc.
+0.87%
+$181,118.74 
NNOX Nano-X Imaging Ltd.
+0.47%
+$417.77 
LEGN Legend Biotech Corporation American Depositary Shares
-7.63%
-$1.6M 
NBTX Nanobiotix S.A. American Depositary Shares
-5.24%
-$12.26M 
CTNM Contineum Therapeutics, Inc.
-2.75%
-$791,669.2 
ACET Adicet Bio, Inc.
-2.72%
-$5,466.96 
RAPP Rapport Therapeutics Inc.
-2.65%
-$1.96M 
PRCT Procept BioRobotics Corporation
-1.32%
-$91,274.45 
FATE Fate Therapeutics Inc.
-1%
-$101,371.92 
VOR Vor Biopharma Inc.
-0.76%
-$7,522.48 
XNCR Xencor Inc.
-0.17%
-$18,701.55 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 66 | Longs Won 15/66 22% | Profit Factor 1.1 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $48.72M |
| Average Win $36.41M | Best Trade (Jul 09) $293.71M | Sharpe Ratio -5.88 |
| Average Loss -$9.76M | Worst Trade (Jul 15) -$190.28M | Z-Score 1.89 (94.14%) |
| Commissions $0 | Avg. Trade Length 2y 3m 1w 5d | Expectancy $729,748.05 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 83 | 75 | 67 | 58 | 50 | 42 | 33 | 25 | 17 | 8 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
